Business Wire

EXFO Partners With Openreach for Ground-Breaking Full Fibre Initiative

7.1.2021 13:17:00 EET | Business Wire | Press release

Share

EXFO Inc. (NASDAQ: EXFO, TSX: EXF), the communications industry’s test, monitoring and analytics experts, and Openreach, the United Kingdom’s largest digital infrastructure firm, today announced their collaboration on a major initiative to accelerate Full Fibre deployment, and enhance the quality of build and experience for customers across the UK.

The project is essential for delivering next-generation Fibre-to-the-Premises (FTTP) networks, which provide the digital infrastructure required to work, learn and socialize. As part of its industry-leading Fibre First programme, Openreach has committed to delivering 20 million homes passed with FTTP by the mid-to late 2020s, assuming it has the right investment conditions. Openreach has also committed to building out this new digital infrastructure to 4.5 million premises by the end of March 2021.

Following a competitive tender process, Openreach has awarded EXFO a contract to supply optical test heads and test access switching for this initiative. With its cloud-based Nova Fiber solution, EXFO will equip Openreach to assure its build, thereby accelerating the programme and avoiding costly return visits to fix connection problems—additional “truck rolls” more than double operators testing costs.1 Following installation, Openreach will be able to remotely monitor its fibre infrastructure supporting the in-life operations of its Full Fibre service.

This announcement comes as Openreach hit a record build rate for its Full Fibre broadband programme. Openreach engineers are now delivering faster, more reliable connectivity to another 40,000 homes and businesses every week, or the equivalent of a home every 15 seconds.

Peter Bell, Director, Network Technology, Openreach: “We know that now more than ever that being connected matters. We’re convinced that our new Full Fibre network can play a crucial role in keeping the nation connected. This year, our build has been gathering pace and momentum, and we’re determined to match that rapid speed of deployment with the highest standards of build quality build and customer service.

EXFO will help us get there. As a long-term Openreach partner, EXFO was selected thanks to its proven ability to provide fast, automated qualification of fibre builds, and for its unique iOLM OTDR technology. We’re committed to working with the best-in-class to maintain our position as the UK’s leading Full Fibre builder and we’re excited to lead the way as we continue to deliver high-quality network connections to homes and businesses across the UK.”

Wim te Niet, Vice President, Sales – EMEA, EXFO: “Openreach is an early mover in adopting permanent fibre monitoring technology, which will eventually cover all households in the UK. Currently, the FTTH/B penetration rate in the UK stands at 18%2, and Openreach has an ambitious plan to build out Full Fibre to millions of households and businesses. We see a similar wave in other key European markets like Germany. I believe network operators across Europe will soon follow Openreach’s lead to ensure first-time-right installations, reduce turn-up failures, and substantially reduce truck rolls for service calls. As for markets with high FTTH/B penetration rates, telecom operators are finding they need sophisticated automated monitoring tools to ensure superior customer experience. EXFO’s innovative Nova Fiber solution gives them these abilities.”

About EXFO
EXFO (NASDAQ: EXFO) (TSX: EXF) develops smarter test, monitoring and analytics solutions for fixed and mobile network operators, webscale companies and equipment manufacturers in the global communications industry. Our customers count on us to deliver superior network performance, service reliability and subscriber insights. They count on our unique blend of equipment, software and services to accelerate digital transformations related to fibre, 4G/LTE and 5G deployments. They count on our expertise with automation, real-time troubleshooting and big data analytics, which are critical to their business performance. We’ve spent over 35 years earning this trust, and today 1,900 EXFO employees in over 25 countries work side by side with our customers in the lab, field, data center and beyond.

About Openreach
Openreach Limited is the UK’s digital network business. We’re 35,000 people, working in every community to connect homes, schools, shops, banks, hospitals, libraries, mobile phone masts, broadcasters, governments and businesses – large and small – to the world. Our mission is to build the best possible network, with the highest quality service, making sure that everyone in the UK can be connected. We work on behalf of more than 660 communications providers like SKY, TalkTalk, Vodafone, BT and Zen, and our broadband network is the biggest in the UK, passing more than 31.8m UK premises. Over the last decade we’ve invested more than £14 billion into our network and, at more than 185 million kilometres, it’s now long enough to wrap around the world 4,617 times. Today we’re building an even faster, more reliable and future-proof broadband network which will be the UK’s digital platform for decades to come. We’re making progress towards our FTTP target to reach 20m premises by mid-to late 2020s. We’ve also hired more than 3,000 trainee engineers this past financial year to help us build that network and deliver better service across the country. Openreach is a highly regulated, wholly owned, and independently governed unit of the BT Group. More than 90 per cent of our revenues come from services that are regulated by Ofcom and any company can access our products under equivalent prices, terms and conditions. For the year ended 31 March 2020, we reported revenue of £5bn.

For more information, visit  www.openreach.co.uk/.
Email: press@openreach.co.uk

Forward-Looking Statements - EXFO
This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and we intend that such forward-looking statements be subject to the safe harbors created thereby. Forward-looking statements are statements other than historical information or statements of current condition. Words such as may, expect, believe, plan, anticipate, intend, could, estimate, continue, or similar expressions or the negative of such expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events and circumstances are considered forward-looking statements. They are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those in forward-looking statements due to various factors including, but not limited to, macroeconomic uncertainty, including trade wars and recessions; our ability to successfully integrate businesses that we acquire; capital spending and network deployment levels in the communications industry (including our ability to quickly adapt cost structures to anticipated levels of business and our ability to manage inventory levels with market demand); future economic, competitive, financial and market conditions; consolidation in the global communications test, monitoring and analytics solutions markets and increased competition among vendors; capacity to adapt our future product offering to future technological changes; limited visibility with regard to the timing and nature of customer orders; delay in revenue recognition due to longer sales cycles for complex systems involving customers’ acceptance; fluctuating exchange rates; concentration of sales; timely release and market acceptance of our new products and other upcoming products; our ability to successfully expand international operations and to conduct business internationally; and the retention of key technical and management personnel. Assumptions relating to the foregoing involve judgments and risks, all of which are difficult or impossible to predict and many of which are beyond our control. Other risk factors that may affect our future performance and operations are detailed in our Annual Report, on Form 20-F, and our other filings with the U.S. Securities and Exchange Commission and the Canadian securities commissions. We believe that the expectations reflected in the forward-looking statements are reasonable based on information currently available to us, but we cannot assure you that the expectations will prove to have been correct. Accordingly, you should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this document. Unless required by law or applicable regulations, we undertake no obligation to revise or update any of them to reflect events or circumstances that occur after the date of this document.


1 Omnia operator survey: test and measurement efficiency (2020)
2 Data taken from recent Ofcom Connected Nations report 2020

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For information:
CCgroup, for EXFO:
Wilf Collins
+44 7719 989 444
Chloe Pope
+44 7741 242 227
exfo@ccgrouppr.com

Vance Oliver
Director, Investor Relations
(418) 683-0913, ext. 23733
vance.oliver@exfo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye